Send us a Text Message.

Dr. Raj Yavatkar, Ph.D. is Chief Technology Officer at Juniper Networks ( https://www.juniper.net/us/en/the-feed/topics/raj-yavatkar.html ), where he has responsibility for charting the company’s technology strategy, leading and executing the company’s critical innovations and products for intelligent self-driving networks, security, Mobile Edge Cloud, network virtualization, packet-optical integration, and hybrid cloud. A technology and products pioneer throughout his career, Dr. Yavatkar has envisioned how emerging technologies can be applied to creatively solve enterprise and business problems ahead of competitors to help establish new product lines. Before joining Juniper, Dr. Yavatkar was at Google (GCP), where he led a large team of engineers to deliver cloud networking infrastructure and products for Google Cloud customers. Prior to that at VMware, he ideated a new product concept to address the private/hybrid cloud markets by defining VMware Cloud Foundation—an easy way to deploy and manage virtual clouds—leading a large product team to successfully deliver product to market. He started his career at Intel, rising to the position of Intel Fellow, a position he held for 10 years. During his various leadership roles there, Dr. Yavatkar was responsible for driving new product and R&D initiatives in many areas of software. He brings a wealth of experience in emerging technologies. He has been awarded more than 45 patents, published over 60 research papers, authored 5 Internet standards, and co-authored a book on internet quality of service. He is an IEEE Fellow and holds a PhD in Computer Science from Purdue University.

Support the Show.

Send us a Text Message.

Dr. Jasneet Bhullar, MD, MS, is a colorectal surgeon and member of the general surgery team, Ascension Providence Hospital, Michigan State University College of Human Medicine ( https://healthcare.ascension.org/find-care/provider/1316177876/jasneet-bhullar ), where he provides both surgical and non-surgical treatments for a range of conditions including pelvic floor disorders, fecal incontinence, colon and rectal cancer, hemorrhoids, and other complex issues of the colon and rectal system.

Dr. Bhullar is also a practitioner with the Cornerstone Medical Group ( https://www.cornerstonemedgroup.com/physicians-staff/jasneet-bhullar-md/ ), a multi-specialty group consisting of primary care and specialty physicians in the metro Detroit area, where he was responsible for earning recognition as an Medtronic InterStim™ Center of Excellence for his work with their MRI-compatible implantable neuromodulation technology for Fecal incontinence (FI).

Dr. Bhullar earned his medical degree at Guru Gobind Singh Medical College in India and completed residencies in general surgery through Government Medical College, India and Providence Hospital and Medical Centers — Michigan State University, and did a fellowship in colon and rectal surgery at the University of Minnesota. He is board-certified by the American Board of Surgery (ABS) and the American Board of Colon and Rectal Surgery (ABCRS).

Support the Show.

Send us a Text Message.

Cary Claiborne is CEO of Adial Pharmaceuticals ( https://www.adial.com/ ), a clinical-stage biopharma company focused on developing therapies for the treatment of addiction and related diseases, specifically Alcohol Use Disorder (AUD). In the U.S. alone, an estimated 35 million people suffer from AUD, resulting in significant health, social and financial costs. Current treatment options present significant barriers to patient adoption, including abstinence and side effects, which can lead to social stigmatization.

Mr. Claiborne has over three decades of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies.

Most recently, Mr. Claiborne served as Chief Financial Officer and director of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. He led Indivior’s spin-off from its then parent company, Reckitt Benckiser, to become an independent, publicly traded company.

Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt.

Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc. during the company’s initial public offering.

Mr. Claiborne currently sits on the boards of NeuroSense Therapeutics, a clinical-stage drug development company that is advancing a treatment for people living with amyotrophic lateral sclerosis, and CytRx Corporation, a biopharmaceutical company focused on discovering and developing new cancer therapeutics.

Mr. Claiborne graduated from Rutgers University with a B.A. in Business Administration and earned his M.B.A from Villanova University and was a National Association of Corporate Directors (NACD) Governance Fellow.

Support the Show.